AB-4000 series / ArsenalBio, BMS - LARVOL DELTA

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors (GlobeNewswire) - "Arsenal Biosciences, Inc...announced that Bristol Myers Squibb (NYSE:BMY) has exercised its exclusive license option for ArsenalBio’s AB-4000 series, the lead collaboration program generated under the multi-program agreement signed in December 2020....ArsenalBio remains eligible for additional milestone payments as the programs and collaboration advance, as well as royalties on potential commercial sales."

Licensing / partnership • Oncology • Solid Tumor